The Class B term loan is intended to support origination growth and platform expansion at the Morristown, New Jersey equipment-finance company.

The regional survey still showed strong new orders and shipments in September, while input and selling price gauges both moved higher.

North Immunology investors are expected to own about 95.25% of the combined company, with the financing intended to fund development of bispecific antibody candidate NOR-101 into 2028.

The Marea acquisition closed September 17, while Lisata’s $225 million private placement is expected to close September 18 and fund the combined business into 2028.

Three MPC members backed a rise to 4%, while the Bank set a multi-year path to unwind £368 billion of gilts held for monetary policy purposes by the end of 2034.

Energy and petroleum products led the monthly increase in factory-gate prices, while crude energy costs drove the sharper rise in manufacturers’ raw-material inputs.

The merged insurer said close to half of its CHF 650 million annual run-rate savings target was already secured by June, prompting a higher year-end target while merger integration costs remain within guidance.

Proceeds are set to retire most 2028 notes and all 2030 notes, while Grünenthal’s €675 million 2031 secured notes stay outstanding.

The adjustment reflects newly available retirement-benefits accounting data and changes Flow of Funds records from the second quarter of 2025 onward; it does not represent a cut in pension payments.

Regional Network contacts expect moderate growth through the second half as stronger household purchasing power, defence spending and data-centre construction offset weak building activity.